Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection Fraction
This exploratory substudy of the Empire HF, treatment with empagliflozin exerted no overall effect on RV function in stable HFrEF patients, but significantly improved RVFWS in patients in the lowest tertile of RVFWS after 12 weeks of treatment. Trial Registration ClinicalTrials.gov, Unique Identifier: NCT03198585.
Authors
- Finn Gustafsson (ORCID: https://orcid.org/0000-0003-2144-341X)
- Barry A. Borlaug (ORCID: https://orcid.org/0000-0001-9375-0596)
- Lars Køber (ORCID: https://orcid.org/0000-0002-6635-1466)
- Lars Eriksen Videbæk
- Jesper Rindom Jensen (ORCID: https://orcid.org/0000-0001-6023-8270)
- Massar Omar
- Sören Möller (ORCID: https://orcid.org/0000-0003-0858-4269)
- Caroline Kistorp (ORCID: https://orcid.org/0000-0002-3019-6775)
- Peter Frederiksen (ORCID: https://orcid.org/0000-0003-3712-7980)
- Mulham Ali
- Christian Tuxen
- Jacob Eifer Møller (ORCID: https://orcid.org/0000-0003-2873-5845)
- M I Poulsen
- Morten Schou
Institutions
- University of Copenhagen (DK)
- Mayo Clinic (US)
- University of Southern Denmark (DK)
- Frederiksberg Hospital (DK)
- Odense University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1093/eschf/xvaf031
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00